MAJOR PAPERS:

• Countrywide Financial Corporation (NYSE: CFC) announced another 900 job cuts as the company slashes costs in the face of a drop in lending volumes and rising defaults, The Wall Street Journal reported.
• Barron's Online's "Inside Scoop" section reported that CVS Caremark Corporation (NYSE: CVS) chairman Edwin Crawford sold 120K shares worth $45.4M Friday and Tuesday after exercising the same number of options for $2.8M.

OTHER PAPERS:

• Italian carmaker Fiat (OTC: FIATY) is negotiating with India's Tata Motors Limited (NYSE: TTM) on a joint bid for Ford Motor Company's (NYSE: F) Jaguar and Land Rover divisions, reported the Telegraph.
• British mobile telecom company Vodafone Group (NYSE: VOD) has received a $2B tax bill from the Indian government, reported the U.K. Times.
• The Economic Times reported, citing a source close to the development, that Ranbaxy has joined the bidding on Bradley Pharmaceuticals Inc (NYSE: BDY) by placing a preliminary non-binding bid on the company.

MAJOR PAPERS:

• Ratan Tata, chairman of the Tata Group of India, has confirmed his interest in the Jaguar and Land Rover units of Ford Motor Company (NYSE: F), according to the Wall Street Journal.

OTHER PAPERS:

• The Washington Post reported that Home Depot Inc (NYSE: HD) has made a deal to sell its supply arm, HD Supply, for $8.5B, down from the original price of $10.3B, to a consortium of private equity firms headed by Carlyle Group, inside sources say.
• According to a sources with knowledge of the discussions, Altria Group Inc (NYSE: MO) is considering spinning off its Philip Morris International division as part of a restructuring plan to increase shareholder value, reported the New York Times.
• A Chinese technology company has expressed interest in buying Seagate Technology (NYSE: STX), reported the New York Times.
• According to senior industry analysts, Dr. Reddy's Laboratories (NYSE: RDY) is eyeing U.S. based Bradley Pharmaceuticals Inc (NYSE: BDY), which is expected to be valued at between $380M-$400M, reported the Economic Times.

MOST NOTEWORTHY: Ethanol producers Novacea, Inc. (NOVC) and Aimco (AIV) were today's noteworthy downgrades:

• Banc of America downgraded shares of Andersons Inc. (NASDAQ: ANDE) to Neutral from Buy, as well as VeraSun Energy (NYSE: VSE), Pacific Ethanol (NASDAQ: PEIX) and Aventine Renewable Energy (NYSE: AVR) to Sell from Neutral. The firm believes new ethanol supply will depress ethanol's premium to gasoline, drive corn prices higher and pressure distillers' grains values.
• Novacea Inc. (NASDAQ: NOVC) was downgraded to Peer Perform from Outperform at Bear Stearns based on valuation and lack of catalysts until 2H08; the firm believes the company's deal with Schering-Plough (NYSE: SGP) is a positive.
• Aimco Properties (NYSE: AIV) was downgraded to Underweight from Equal Weight at Lehman, as the firm does not view AIV as an attractive takeover target.

OTHER UPGRADES:

• EMC Corp. (NYSE: EMC) was downgraded to Peer Perform from Outperform at Bear Stearns based on valuation.
• UBS downgraded shares of Iomai Corp. (NASDAQ: IOMI) and ICICI Bank (NYSE: IBN) to Neutral from Buy.
• Goldman Sachs downgraded Parexel Intl. (NASDAQ: PRXL) to Neutral from Buy and PRA International (NASDAQ: PRAI) to Sell from Neutral.
• Janus Capital Group (NYSE: JNS) was downgraded to Neutral from Buy at Merrill Lynch.
• Security Bank (NASDAQ: SBKC) was downgraded to Hold from Buy at Sandler, O'Neill & Partners on valuation.
• Bradley Pharmaceuticals (NYSE: BDY) was downgraded to Hold from Buy on valuation at Matrix USA.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).

Although short selling -- the practice of selling borrowed shares with the hope of repaying the loan by buying back the shares at a lower price -- goes against the American belief that stocks always go up, I have long been fascinated with it. Short Stories discusses what works, what doesn't, and what some of the leading lights in shorting stocks think about its opportunities and threats. I describe possible short trades and I seek your comments and questions for story ideas. I don't offer any investment advice and I don't trade on any of the posts I write.

On October 8 I wrote about Bradley Pharmaceuticals (NYSE: BDY) arguing that I would stay away from the stock which was vulnerable both to a short squeeze and to weak fundamentals. Well, according to TheStreet.com, the short squeeze argument won out -- after BDY's CEO offered to take the company private at a 17% premium over its last closing price.

If you had found the short squeeze argument compelling, you could have bought the stock at $16.47 back on October 8 and could lock in a 37% profit if you sold today at its current $22.49. I find this interesting since BDY's CEO offered a lower price -- $21.50 a share.